The development of anti-heart autoantibody following experimental myocardial infarction in dogs was studied with respect to (1) the subcellular localization of the heart autoantigen(s), (2) the incidence of autoantibody following myocardial infarction, and (3) the temporal development of the autoantibody and its relation to serum enzyme elevations and electrocardiographic changes. Complement-fixing anti-heart autoantibody developed following myocardial infarction induced by either two-stage coronary artery ligation or by the injection of microspheres directly into the coronary circulation. The autoantibody was directed toward an autoantigen residing in the mitochondrial fraction of myocardial tissue and was found to be associated with the 19S class of immunoglobulin, Eighteen of 20 dogs with infarction produced anti-heart mitochondria autoantibody 10 days following induction of myocardial damage; the autoantibody persisted 4 to 6 weeks thereafter. In these dogs the presence of anti-heart mitochondria autoantibody was diagnostic of myocardial infarction at times when the serum enzymes and electrocardiograms were within normal limits. Our studies indicate that a serologic test, based on the detection of complement-fixing anti-heart mitochondria autoantibody, may be a valuable adjunct to tests currently available for diagnosing recent myocardial infarction.
• The diagnosis of myocardial infarction is based on a history of recent chest pain, specific changes in the electrocardiogram, and elevation of various serum enzymes. In many instances the history of chest pain is absent, transient or nonspecific and the changes in serum enzymes are variable and not organ specific. Furthermore, the diagnosis of myocardial infarction often is difficult one or more weeks following an episode of chest pain. At this time the serum enzymes usually are not elevated and the electrocardiograms often are not diagnostic. The development of a sensitive test which could diagnose a myocardial infarction one or more weeks following myocardial damage would be a valuable adjunct to tests currently available. Our present investigations were undertaken to develop such a test based on the development of anti-heart autoantibody following destruction of myocardial tissue.
The development of autoantibody following necrosis of various tissues appears to be a normal physiological process (1) . Anti-heart autoantibodies have been detected in a variety of cardiac diseases, including myocardial infarction (2) . However, the incidence of anti-heart autoantibody in patients following myocardial infarction has varied from 3 to 80%. This variability has precluded its diagnostic applicability. This inconsistency in the demonstration of anti-heart autoantibody can be ascribed to the diverse nature of the immunologic tests and test antigens which have been employed. In previous studies (3, 4) serologic tests based on the utilization of complement following antigen-antibody interaction have yielded the highest incidence of anti-heart autoantibody. Therefore the complement fixation test was used in the present study.
To develop a serologic, diagnostic test for recent myocardial damage, we employed an experimental model in dogs whereby the presence of anti-heart autoantibody following myocardial infarction could be studied systematically under controlled conditions with respect to (1) the localization of the heart autoantigen (s) on the various subcellular organelles; (2) the incidence of autoantibody following myocardial infarction; and (3) the temporal development of the autoantibody and its relation to serum enzyme elevations and electrocardiographic changes.
Methods
Acute myocardial infarctions were produced in adult mongrel dogs weighing 10 to 25 kg by the two-stage coronary artery ligation technique of Harris (5) or by the selective injection of sized microspheres into the left coronary artery (6) . For both procedures the dogs were anesthetized by intravenous injection of sodium pentobarbital, 30 mg/kg. Twelve dogs underwent thoraeotomy. In each animal the anterior descending branch of the left coronary artery was dissected free 1 cm distal to the left atrial appendage. In seven animals the coronary artery was occluded by two ligatures. The first ligature caused constriction without complete occlusion and the second, placed 30 minutes later, occluded the coronary artery. Forty mg of intravenous lidocaine was administered upon constriction with the first ligature and upon occlusion with the second ligature to prevent arrhythmias. Five control animals were treated in die same manner surgically with the exception that the ligatures were removed without constriction of the coronary artery. All of the animals survived and were killed 4-6 weeks after surgery.
Twenty-five anesthetized dogs underwent selective left coronary artery catheterization. With an aseptic technique, a no. 8 Ducor preformed coronary catheter was guided under fluoroscopic control from the left femoral artery into the left Circulation Research, Vol. XXIX, September 1971 coronary artery. Catheter tip position was verified by the injection of 5 ml of Hypaque, 75%. Following 40 mg of intravenous lidocaine to prevent arrhythmias, left coronary artery embolization was induced in 13 of these animals by injecting Dowex resin microspheres (297-350u, diam), 0.05 mg/kg estimated heart weight (7) . The microspheres were suspended in 5 ml of 10% low molecular weight dextran and were injected as a bolus followed with a 5 ml saline flush. Following embolization, the femoral artery continuity was restored and the skin incision closed. The 12 control animals in this group were treated in the same manner except that the bolus of dextran injected into the left coronary artery did not contain microspheres. These animals were followed for 4-6 weeks before they were killed.
In both groups of dogs venous blood samples were obtained 6, 12 and 24 hours following the experimental procedures. Thereafter, blood samples were obtained daily for the first 10 days and then every third day until death. Serum levels of creatine phospholdnase and glutamic oxalacetic transaminase were determined spectrophotometrically using procedures described by Bergmeyer (8) . Six limb lead electrocardiograms were taken on alternate days during the first week following the experimental procedures and at 7-day intervals for 30-66 days. The animals were killed by large doses of sodium pentobarbital. A complete postmortem examination was performed on each animal, and myocardial tissue was preserved in 1015 buffered formalin for microscopic examination.
The temporal development of anti-heart autoantibody was assessed by a micro-complement fixation test using a microtiter apparatus (Cooke Engineering Co., Alexandria, Virginia). Doubling dilutions of heat-inactivated (56° C for 30 minutes) sera were made in 25 //.liters of 0.15M sodium barbital-buffered saline pH 7.3 (9) containing 0.1% dog albumin. Complement fixation was determined by adding 25 /^liters of a dilution of guinea pig serum containing 1.50 minimal hemolytic doses of complement followed by 25 /iliters of the respective autologous or homologous subcellular heart autoantigens. The reaction was allowed to proceed at 37° C for 30 minutes and then 25 /^liters of a 1.5% suspension of sensitized sheep erythrocytes was added and the reaction was allowed to continue at 37° C for 40 minutes. The microtiter plates were centrifuged at 1,000 rpm for 5 minutes and the degree of hemolysis was estimated by visual inspection. The autoantibody n'ter was defined as the highest dilution of serum at which incomplete hemolysis had occurred as judged by clearly visible sheep erythrocytes. The optimal concentration of the myocardial antigen was determined by checker-board titration using a serum containing antiheart autoantibody. Appropriate antibody and antigen controls were performed simultaneously. A standard anti-heart mitochondria autoantibody serum was titrated to insure uniformity of the complement fixation test from day to day.
Dog myocardial tissue was fractionated into its subcellular constituents to localize the autoantigenic activity. The heart was removed immediately after death, washed, trimmed of fat and connective tissue and homogenized in 0.25M sucrose with a Polytron tissue disintegrator (setting 5, 20 seconds). The crude homogenate was centrifuged at 600 g for 13 minutes. The resulting pellet containing the cellular debris and the nuclear fraction was resuspended in 0.25M sucrose, centrifuged at 1000 g for 10 minutes' and resuspended in sucrose. The 600 g supernatant was centrifuged at 5500 g for 13 minutes and the pellet containing the mitochondria was resuspended, centrifuged at 6500 g for 10 minutes, and resuspended in 0.25 M sucrose. The 5500 g supernatant fluid was centrifuged at 17,000 g, and the supernatant fluid was then recentrifuged at 105,000 g for 60 minutes. The pellet from this operation contained the microsomes and the supernatant fluid consisted of the cytosol. The protein content of each subcellular fraction was estimated by a Biuret procedure (10) . The cytochrome oxidase content of the various cell fractions was determined as described by Schnaitman et al. (11). Cytochrome oxidase activity was used to determine the presence of mitochondrial contamination in the various subcellular fractions.
Sera with diagnostic anti-heart mitochondria autoantibody were separated into 7S (fractions 3-5) and 19S (fractions 6-10) components by a modified sucrose density gradient ultraeentrifugation procedure (12) . The sucrose solutions were prepared in the buffer used in the complement fixation test without the dog albumin supplement. The sera were placed on the gradients and were centrifuged at 35,000 rpm for 18 hours in a Beckman model L ulrracentrifuge, SW 50 rotor. Ten 0.5 ml fractions were removed from the top of the gradient and were tested immediately for anti-heart mitochondria autoantibody.
Results
Initial experiments were performed to localize and to isolate a heart autoantigen to be used for the detection of anti-heart autoantibody. Such a standardized preparation of purified heart autoantigen would provide the most sensitive and reproducible complement fixation assay for detecting antiheart autoantibody following experimental myocardial infarction. To determine the autoantigenic locus, dog myocardial tissue was fractionated into its subcellular constituents. Checkerboard titrations were performed using these subcellular fractions and sera obtained from dogs with infarction. These sera contained complement-fixing anti-heart autoantibody when crude dog heart homogenate was used as the test antigen. The results of these checkerboard titrations are shown in Table 1 . As can be seen, the autoantigenic activity resided in the mitochondrial fraction of dog myocardial tissue. Although autoantigenic activity could be detected with mitochondria in concentrations less than 40 /ig protein/ml, this quantity of mitochondria was used throughout the remainder of the study and provided the most sensitive assay for antiheart autoantibody using the complement fixation test. Microsomes and cytosol contained no detectable autoantigenic activity and the nuclei contained only trace activity even when large concentrations (200 fig protein/ ml) of these fractions were used in the complement fixation test. The presence of mitochondria in the subcellular fractions was assessed using cytochrome oxidase activity as a mitochondrial membrane marker. As shown Sucrose density gradient ultracentrifugation of antiheart mitochondria autoantibody.
in Table 1 , the small amount of autoantigenic activity of the nuclear fraction could be ascribed to contamination of this fraction with mitochondria. Sera obtained 14 days following coronary artery ligation and microsphere embolization were fractionated by sucrose density gradient ultracentrifugation to determine whether the induced anti-heart mitochondria autoantibody was associated with the 7S or 19S class of immunoglobulins. The results of these gradient centrifugation studies are shown in Figure  1 . Complement-fixing autoantibody activity was detected only in fractions 6-10 which contain the 19S immunoglobulins. Identical results were obtained with sera from dogs possessing preexisting anti-heart mitochondria autoantibody prior to infarction and with sera obtained at the time of death.
The incidence of anti-heart mitochondria autoantibody in seven dogs following ligation of the anterior descending branch of the left coronary artery is depicted in Table 2 . All seven dogs with infarction produced antiheart autoantibody in titers ranging from 1:128 to 1:1024. The autoantibody titers following myocardial infarction were identical whether homologous or autologous heart mitochondria were used as the test antigen. . Serial electrocardiograms revealed unequivocal myocardial infarction with the development of pathologic Q waves, ST-segment elevation and T-wave inversion. Myocardial infarction was confirmed at autopsy and demonstrated that the ligation of the left coronary artery produced large transmural left ventricular myocardial infarctions in every dog. The control dogs that underwent thoracotomy without coronary artery ligation did not produce detectable anti-heart mitochondria autoantibody and their serum enzymes, electrocardiograms and autopsy findings were normal. Figure 2 illustrates the temporal development of anti-heart mitochondria autoantibody Temporal development of anti-heart mitochondria autoantibody following coronary artery ligation. Neither the dogs with coronary ligation nor those with control thoracotomy had anti-heart mitochondria autoantibody prior to surgery. CPK = creatine phosphokinase.
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FIGURE 3
Temporal development of anti-heart mitochondria autoantibody following coronary artery ligation. Both the ligated and the control thoracotomy dogs had preexisting anti-heart mitochondria autoantibody prior to surgery. CPK = creatine phosphokinase.
following induction of myocardial infarction by coronary artery ligation in a dog that did not have preexisting autoantibody. Anti-heart mitochondria autoantibody was detected 10 days following myocardial infarction, reached maximal titers by day 15, and persisted for approximately 2 weeks. As illustrated in Figure 2 , serum creatine phosphokinase increased to its maximum level within 24 hours and returned to normal by day 3. A control dog also shown in this figure had neither an increase in serum creatine phosphokinase nor the development of anti-heart mitochondria autoantibody during the 30-day test period. Figure 3 illustrates the temporal develop-ment of anti-heart mitochondria autoantibody following myocardial infarction in a dog that had low levels (1:32) of anti-heart mitochondria autoantibody prior to the induction of myocardial infarction. Two days following myocardial infarction, the preexisting autoantibody titer decreased to barely detectable levels (1:4). On day 10, the anti-heart mitochondria autoantibody titer increased to levels (1:512) appreciably greater than the preexisting titer. In addition, Figure 3 shows the autoantibody titers of a control thoracotomy dog which had preexisting anti-heart mitochondria body. During the entire experimental period the anti-heart autoantibody titer 
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Microsphere injection (13) Control catheterization (12) Number of dogs is in parentheses. Temporal development of anti-heart mitochondria autoantibody following the injection of microspheres into the left coronary artery. Both the dogs with microsphere-induced infarction and those with control catheterization had anti-heart mitochondria autoantibody prior to the experimental procedure. CPK = creatine phosphokinase. did not rise or fall significantly and the serum creatine phosphokinase remained constant.
The incidence of diagnostic anti-heart mitochondria autoantibody in dogs with infarction caused by selective microsphere injection is shown in Table 3 . Eleven of 13 dogs with infarction caused by microsphere injection produced anti-heart autoantibody. Six of these 11 dogs positive for autoantibody had unequivocal evidence of myocardial infarction as determined by elevated serum enzymes and electrocardiographic changes. However, microsphere infarction in 5 of the 11 positive dogs did not produce both elevated serum enzymes and electrocardiographic changes. Myocardial infarction in these five dogs was confirmed only after postmortem examination. Two of these five did not have elevated serum enzymes but had electrocardiographic evidence consistent with myocardial infarction. Three of the five positive dogs had elevated serum enzymes but did not have electrocardiographic changes. The two dogs which did not produce diagnostic anti-heart mitochondria autoantibody following myocardial infarction had changes in both serum enzymes and electrocardiograms consistent with myocardial infarction. The 12 control catheterization dogs that received no microspheres did not develop diagnostic mitochondria autoantibody and their serum enzymes and electrocardiograms were normal. Figure 4 illustrates the temporal development of autoantibody in a representative dog which had unequivocal serum enzyme and electrocardiographic evidence of myocardial infarction following injection of microspheres into the left coronary artery. The preexisting levels (1:32) of anti-heart mitochondria autoantibody disappeared by day 2. On day 10 the autoantibody titer increased, reached maximum titers (1:256) on day 14, and persisted for 2 weeks. The preexisting antiheart mitochondria autoantibody titer in a control dog, shown in Figure 4 , remained constant throughout the test period. The serum enzymes and electrocardiograms in this dog were normal. Figure 5 illustrates the elevation of antiheart autoantibody in a dog that had an Teni/joiul development of anti-heart mitochondria autoantibody following injection of microspheres into the left coronary artery. The dog with microsphereinduced infarction had anti-heart mitochondria autobody prior to the experimental procedure and the dog with control catheterization did not. CPK = creatine phosphokinase.
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elevation of serum enzymes after microsphere injection but did not have electrocardiographic evidence of myocardial infarction. In contrast to the autoantibody titers of the dog with infarction shown in Figure 4 , the preexisting level of anti-heart mitochondria autoantibody did not decrease following the injection of microspheres. On day 14, the autoantibody titers increased to a maximum by day 20 and decreased thereafter. Figure 5 also illustrates the absence of preexisting antiheart mitochondria autoantibody in a control catheterization dog. Anti-heart mitochondria autoantibody did not develop during the 30day test period following coronary catheterization and the serum enzymes were normal. Figure 6 illustrates the development of antiheart mitochondria autoantibody in a dog that did not have elevated serum enzymes following the injection of microspheres into the coronary circulation. The preexisting autoantibody titer did not decrease following the injection of microspheres. On the sixth day, the autoantibody titer gradually increased, reached a maximum level on day 18, and maintained this level for 22 days. Initially, the electrocardiograms of this dog did not show evidence of myocardial infarction. However, an electrocardiogram Temporal development of anti-heart mitochondria autoantibody following the injection of microspheres into the left coronary artery. CPK = creatine phosphoklnase; GOT = glutamic oxalacetic transaminase. taken 10 days following the injection of microspheres showed ST-segment elevation and T-wave inversion in leads I and AVL diagnostic of an anterior wall myocardial infarction. A terminal electrocardiogram on this dog showed marked T-wave inversion also compatible with a recent myocardial infarction. Gross postmortem examination did not show definite myocardial infarction. However, microscopic examination of tissue sections revealed evidence of myocardial necrosis consistent with myocardial infarction.
Discussion
The large variation in the incidence of antiheart autoantibody in patients following myocardial infarction has precluded the development of a diagnostic, serologic test for detecting myocardial necrosis. Three tests, which have been utilized to measure antiheart autoantibody, have yielded the following incidences of autoantibody after myocardial infarction: passive hemagglutination, 22-54$ (13) (14) (15) (16) (17) ; immunofluorescence, 10-50$ (18) (19) (20) (21) ; techniques based upon the consumption of complement, 50-81$ (3, 4) . Variations in the antigen preparations that have been employed in these studies may have influenced the detection of anti-heart autoantibody. Investigators using the passive hemagglutination technique (13) (14) (15) (16) (17) have employed soluble heart extracts, and studies based upon the consumption of complement (3) have used the sedimentable fraction of heart homogenates as the test antigen. Therefore it is likely that the above variations may have been a result of the detection of anti-heart autoantibodies of differing specificities directed against at least two constituents of heart tissue. Indeed, Gery et al. (22) have demonstrated in rats that complement fixing antiheart antibody is directed towards particulate bovine heart antigens while passive hemagglutinating antibody is directed solely toward the unsedimentable, soluble heart constituents.
Few studies have been instituted to characterize the temporal development of anti-heart The present studies have demonstrated that diagnostic, anti-heart mitochondria autoantibody was produced in 90% of dogs following experimental myocardial infarction. The complement-fixing autoantibody was associated with the 19S class of immunoglobulin. Because Fujimoto (25) has demonstrated that dog IgM is the only immunoglobulin which has a sedimentation coefficient of 19S, we have concluded that the anti-heart mitochondria autoantibody is IgM. The titers of antiheart mitochondria autoantibody were the same whether autologous or homologous heart mitochondria were used as the test antigen. This demonstrates that the antigenic determinants) on the dog heart mitochondria test antigens were autoantigens.
The variations in the temporal development of diagnostic anti-heart mitochondria autoantibody following myocardial infarction (Figs. 2-6) may be attributed to differences either in the immunologic responsiveness of individual dogs or, more likely, in the size or the development of the induced myocardial necrosis. The 7 dogs with infarction caused by coronary artery ligation had large, transmural myocardial infarctions with unequivocal evidence of myocardial necrosis; ST-segment elevation, T-wave inversion and pathologic Q waves were present during the entire period of observation. However, the electrocardiographic changes in the dogs with infarction caused by injection of microspheres were frequently transient, occurring during the first week. During the 2-4 weeks following microsphere injection, the electrocardiograms usually were normal or nonspecific. Three of these animals had no changes in the electrocardio-Circulation Research, Vol. XXIX, September 1971 grams indicative of myocardial ischemia or infarction during the entire period of observation. The elevations of serum enzymes (creatine phosphokinase and glutamic oxalacetic transaminase) which persisted for only 3-4 days following myocardial infarction, often were variable. Two of the dogs with infarction caused by microspheres had no elevation in serum enzymes but developed diagnostic anti-heart mitochondria autoantibody; the myocardial infarctions were confirmed at postmortem examination.
The present study indicates that a serologic test based on the development of anti-heart mitochondria autoantibody may prove to be a valuable adjunct to tests currently available for detecting myocardial necrosis. Further experiments to characterize the organ specificity of the autoantibody following myocardial necrosis are being performed to avoid false positive results due to necrosis of other tissue such as liver, kidney and lung. We have demonstrated that skeletal muscle damage, which occurred during thoracotomy of the control dogs, did not result in the formation of autoantibody which cross-reacted with heart mitochondria.
To assess the sensitivity of the proposed serologic tests for diagnosing myocardial infarction, it will be necessary to determine the minimum amount of myocardial necrosis to initiate the formation of anti-heart autoantibody. In this regard, two of the dogs in the present study that developed anti-heart autoantibody had insufficient myocardial necrosis to cause an elevation of the serum enzymes. In addition, three other dogs had insufficient myocardial necrosis to cause pathologic changes in the electrocardiograms. However, all five of these dogs produced diagnostic antiheart mitochondria autoantibody. This suggests that a small amount of myocardial necrosis can induce the formation of anti-heart autoantibody when other indicators of myocardial damage are within normal limits.
In summary, our studies provide possible explanations for the variability in the reported incidences of anti-heart mitochondria autoantibody in patients following myocardial infarc-tion. We have demonstrated in dogs that diagnostic anti-heart autoantibody is not detected until the second week following an episode of myocardial damage. Therefore, serum samples obtained and tested for the presence of anti-heart autoantibody prior to this time may give false negative results. Secondly, we have demonstrated that the primary autoantigenic constituent of myocardial tissue, which reacts with the autoantibody induced by myocardial infarction, resides in the mitochondrial fraction. Therefore, antigen preparations which are used to detect the presence of anti-heart autoantibody which do not contain mitochondrial antigens also may give false negative results. If similar autoantibodies are produced in patients following myocardial infarction, the complement-fixation test for anti-heart mitochondria autoantibody may provide a sensitive test for the diagnosis of recent myocardial infarction.
